Skip to main content

Advertisement

SpringerLink
Log in

Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Nitrogen-containing bisphosphonates such as zoledronic acid (ZOL) and pamidronate have been widely and successfully used for the treatment of cancer patients with bone metastases and/or hypercalcemia. Accumulating recent reports have shown that cancer patients who have received these bisphosphonates occasionally manifest bisphosphonate-related osteonecrosis of the jaw (BRONJ) following dental treatments, including tooth extraction. However, little is known about the pathogenesis of BRONJ to date. Here, to understand the underlying pathogenesis of BRONJ, we examined the effects of ZOL on wound healing of the tooth extraction socket using a mouse tooth extraction model. Histomorphometrical analysis revealed that the amount of new bone and the numbers of blood vessels in the socket were significantly decreased in ZOL-treated mice compared to control mice. Consistent with these results, ZOL significantly inhibited angiogenesis induced by vascular endothelial growth factor in vivo and the proliferation of endothelial cells in culture in a dose-dependent manner. In contrast, etidronate, a non-nitrogen-containing bisphosphonate, showed no effects on osteogenesis and angiogenesis in the socket. ZOL also suppressed the migration of oral epithelial cells, which is a crucial step for tooth socket closure. In addition, ZOL promoted the adherence of Streptococcus mutans to hydroxyapatite and the proliferation of oral bacteria obtained from healthy individuals, suggesting that ZOL may increase the bacterial infection. In conclusion, our data suggest that ZOL delays wound healing of the tooth extraction socket by inhibiting osteogenesis and angiogenesis. Our data also suggest that ZOL alters oral bacterial behaviors. These actions of ZOL may be relevant to the pathogenesis of BRONJ.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Rogers MJ, Watts DJ, Russell RG (1997) Overview of bisphosphonates. Cancer (Phila) 80:1652–1660

    Article  CAS  Google Scholar 

  2. Licata AA (2005) Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother 39:668–677

    Article  CAS  PubMed  Google Scholar 

  3. Michaelson MD, Smith MR (2005) Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol 23:8219–8224

    Article  CAS  PubMed  Google Scholar 

  4. Delmas PD (2005) The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol 17:462–466

    CAS  PubMed  Google Scholar 

  5. DiCaprio MR, Enneking WF (2005) Fibrous dysplasia. Pathophysiology, evaluation, and treatment. J Bone Joint Surg [Am] 87:1848–1864

    Article  Google Scholar 

  6. Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N Engl J Med 353:898–908

    Article  CAS  PubMed  Google Scholar 

  7. Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19. Aredia Breast Cancer Study Group. N Engl J Med 335:1785–1791

    Article  CAS  PubMed  Google Scholar 

  8. Ashcroft AJ, Davies FE, Morgan GJ (2003) Aetiology of bone disease and the role of bisphosphonates in multiple myeloma. Lancet Oncol 4:284–292

    Article  CAS  PubMed  Google Scholar 

  9. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS (2002) American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20:3719–3736

    Article  PubMed  Google Scholar 

  10. Coleman RE (2002) Future directions in the treatment and prevention of bone metastases. Am J Clin Oncol 25:S32–S38

    Article  PubMed  Google Scholar 

  11. Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M, Glasmacher A (2001) Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 4:CD003188

  12. Ferretti G, Fabi A, Carlini P, Papaldo P, Cordiali Fei P, Di Cosimo S, Salesi N, Giannarelli D, Alimonti A, Di Cocco B, D’Agosto G, Bordignon V, Trento E, Cognetti F (2005) Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 69:35–43

    Article  CAS  PubMed  Google Scholar 

  13. Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042–4057

    Article  CAS  PubMed  Google Scholar 

  14. Hillner BE, Weeks JC, Desch CE, Smith TJ (2000) Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 18:72–79

    CAS  PubMed  Google Scholar 

  15. Osanai T, Tsuchiya T, Ogino T, Nakahara K (2006) Long-term prevention of skeletal complications by pamidronate in a patient with bone metastasis from endometrial carcinoma: a case report. Gynecol Oncol 100:195–197

    Article  PubMed  Google Scholar 

  16. Smith MR (2005) Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev 31(Suppl 3):19–25

    Article  PubMed  Google Scholar 

  17. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer (Phila) 88:2961–2978

    Article  CAS  Google Scholar 

  18. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581–589

    Article  CAS  PubMed  Google Scholar 

  19. Russell RG, Rogers MJ (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone (NY) 25:97–106

    CAS  Google Scholar 

  20. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117

    Article  PubMed  Google Scholar 

  21. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527–534

    Article  PubMed  Google Scholar 

  22. Pires FR, Miranda A, Cardoso ES, Cardoso AS, Fregnani ER, Pereira CM, Correa ME, Almeida JP, Alves Fde A, Lopes MA, de Almeida OP (2005) Oral avascular bone necrosis associated with chemotherapy and biphosphonate therapy. Oral Dis 11:365–369

    Article  CAS  PubMed  Google Scholar 

  23. Assael LA (2004) New foundations in understanding osteonecrosis of the jaws. J Oral Maxillofac Surg 62:125–126

    Article  PubMed  Google Scholar 

  24. Hellstein JW, Marek CL (2004) Bis-phossy jaw, phossy jaw, and the 21st century: bisphosphonate-associated complications of the jaws. J Oral Maxillofac Surg 62:1563–1565

    Article  PubMed  Google Scholar 

  25. Jimenez-Soriano Y, Bagan JV (2005) Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update. Med Oral Patol Oral Cir Bucal 10(Suppl 2):E88–E91

    PubMed  Google Scholar 

  26. Melo MD, Obeid G (2005) Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition. J Am Dent Assoc 136:1675–1681

    CAS  PubMed  Google Scholar 

  27. Olson KB, Hellie CM, Pienta KJ (2005) Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid. Urology 66:658

    Article  PubMed  Google Scholar 

  28. Vannucchi AM, Ficarra G, Antonioli E, Bosi A (2005) Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol 128:738

    Article  PubMed  Google Scholar 

  29. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws: 2009 update. J Oral Maxillofac Surg 67:2–12

    PubMed  Google Scholar 

  30. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clezardin P (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538–6544

    CAS  PubMed  Google Scholar 

  31. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR (2002) Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055–1061

    Article  CAS  PubMed  Google Scholar 

  32. Hellstein JW, Marek CL (2005) Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 63:682–689

    Article  PubMed  Google Scholar 

  33. Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW (2008) Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg 66:767–775

    Article  PubMed  Google Scholar 

  34. Oikawa T, Sasaki M, Inose M, Shimamura M, Kuboki H, Hirano S, Kumagai H, Ishizuka M, Takeuchi T (1997) Effects of cytogenin, a novel microbial product, on embryonic and tumor cell-induced angiogenic responses in vivo. Anticancer Res 17:1881–1886

    CAS  PubMed  Google Scholar 

  35. Hata K, Nishimura R, Muramatsu S, Matsuda A, Matsubara T, Amano K, Ikeda F, Harley VR, Yoneda T (2008) Paraspeckle protein p54nrb links Sox9-mediated transcription with RNA processing during chondrogenesis in mice. J Clin Invest 118:3098–3108

    Article  CAS  PubMed  Google Scholar 

  36. Yang J, Nandi S (1983) Growth of cultured cells using collagen as substrate. Int Rev Cytol 81:249–286

    Article  CAS  PubMed  Google Scholar 

  37. Kubota Y, Kleinman HK, Martin GR, Lawley TJ (1988) Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol 107:1589–1598

    Article  CAS  PubMed  Google Scholar 

  38. Matsumoto M, Tsuji M, Sasaki H, Fujita K, Nomura R, Nakano K, Shintani S, Ooshima T (2005) Cariogenicity of the probiotic bacterium Lactobacillus salivarius in rats. Caries Res 39:479–483

    Article  CAS  PubMed  Google Scholar 

  39. Muller S, Migianu E, Lecouvey M, Kraemer M, Oudar O (2005) Alendronate inhibits proliferation and invasion of human epidermoid carcinoma cells in vitro. Anticancer Res 25:2655–2660

    CAS  PubMed  Google Scholar 

  40. Ribatti D, Nico B, Mangieri D, Maruotti N, Longo V, Vacca A, Cantatore FP (2007) Neridronate inhibits angiogenesis in vitro and in vivo. Clin Rheumatol 26:1094–1098

    Article  CAS  PubMed  Google Scholar 

  41. Yamagishi S, Abe R, Inagaki Y, Nakamura K, Sugawara H, Inokuma D, Nakamura H, Shimizu T, Takeuchi M, Yoshimura A, Bucala R, Shimizu H, Imaizumi T (2004) Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. Am J Pathol 165:1865–1874

    CAS  PubMed  Google Scholar 

  42. Reid IR (2009) Osteonecrosis of the jaw: who gets it, and why? Bone (NY) 44:4–10

    CAS  Google Scholar 

  43. Allen MR, Burr DB (2008) Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 66:987–994

    Article  PubMed  Google Scholar 

  44. Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC (2009) Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol 45:164–172

    Article  CAS  PubMed  Google Scholar 

  45. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis-Papaiakovou E, Christoulas D, Terpos E, Bamias A (2009) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20:117–120

    Article  CAS  PubMed  Google Scholar 

  46. Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, Farina L, Piva S, Palumbo A, Boccadoro M, Corradini P (2008) Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma 49:2156–2162

    Article  CAS  PubMed  Google Scholar 

  47. Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137–145

    Article  CAS  PubMed  Google Scholar 

  48. Clezardin P (2005) Anti-tumour activity of zoledronic acid. Cancer Treat Rev 31(Suppl 3):1–8

    Google Scholar 

  49. Winter MC, Holen I, Coleman RE (2008) Exploring the antitumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34:453–475

    Google Scholar 

  50. Montalvetti A, Bailey BN, Martin MB, Severin GW, Oldfield E, Docampo R (2001) Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. J Biol Chem 276:33930–33937

    Article  CAS  PubMed  Google Scholar 

  51. Martin MB, Grimley JS, Lewis JC, Heath HT III, Bailey BN, Kendrick H, Yardley V, Caldera A, Lira R, Urbina JA, Moreno SN, Docampo R, Croft SL, Oldfield E (2001) Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. J Med Chem 44:909–916

    Article  CAS  PubMed  Google Scholar 

  52. Frith JC, Monkkonen J, Blackburn GM, Russell RG, Rogers MJ (1997) Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12:1358–1367

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We are grateful to Dr. Yoshinosuke Hamada and Dr. Nariaki Matsuura (Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine) for technical support and helpful discussion. This work was supported in part by Ministry of Education, Science, Sports and Culture Grants-in-Aid for Scientific Research A (TY) and The 21st Century COE Program (TY).

Author information

Authors and Affiliations

  1. Department of Molecular and Cellular Biochemistry, Osaka University Graduate School of Dentistry, 1-8 Yamadaoka, Suita, Osaka, 565-0871, Japan

    Yasuyoshi Kobayashi, Akimi Ueda, Liyang Wang, Kenji Hata & Toshiyuki Yoneda

  2. Department of Fixed Prosthodontics, Osaka University Graduate School of Dentistry, Osaka, Japan

    Yasuyoshi Kobayashi & Hirofumi Yatani

  3. Department of Histology and Cell Biology, Matsumoto Dental University, Nagano, Japan

    Toru Hiraga

  4. Department of Pediatric Dentistry, Osaka University Graduate School of Dentistry, Osaka, Japan

    Michiyo Matsumoto-Nakano

Authors
  1. Yasuyoshi Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toru Hiraga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akimi Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Liyang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michiyo Matsumoto-Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kenji Hata
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hirofumi Yatani
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Toshiyuki Yoneda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Toshiyuki Yoneda.

About this article

Cite this article

Kobayashi, Y., Hiraga, T., Ueda, A. et al. Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice. J Bone Miner Metab 28, 165–175 (2010). https://doi.org/10.1007/s00774-009-0128-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-009-0128-9

Keywords

Search

Navigation